Abstract:Background Osteoarthritis (OA) is the most common joint disease worldwide, but its cause remains unclear. Oestrogen protects against OA, but its clinical use is limited. G protein-coupled receptor 30 (GPR30) is a receptor that binds oestrogen, and GPR30 treatment has benefitted patients with some degenerative diseases. However, its effects on OA prevention and treatment remain unclear. Moreover, several studies have found that activation of estrogen receptors exerting anti-ferroptosis effects, which plays an important role in chondrocyte survival. Therefore, this study explored the general and ferroptosis-related effects and mechanisms of GPR30 in OA. Methods Genome-wide RNA sequencing, western blotting, and immunohistochemistry were used to evaluate GPR30 expression and ferroptosis-related indicators in cartilage tissues from clinical patients. Next, we investigated the effects of G1 (a GPR30 receptor agonist) on the function and pathology of OA in an animal model. We also treated chondrocytes with erastin (ferroptosis agonist) plus G1, G15 (GPR30 receptor antagonist), GPR30 short hairpin RNA, or ferrostatin-1 (ferroptosis inhibitor), then measured cell viability and ferroptosis-related indices and performed proteomics analyses. Finally, western blotting and reverse transcription-polymerase chain reaction were used to assess the effects of G1 on yes-associated protein 1 (YAP1) and ferritin heavy chain 1 (FTH1) expression. Results GPR30 expression was lower in the OA cartilage tissues than in the normal tissues, and G1 treatment significantly improved the locomotor ability of mice. Moreover, chondrocyte cell viability significantly decreased after erastin treatment, but G1 treatment concentration-dependently mitigated this effect. Furthermore, G1 treatment decreased phosphorylated YAP1 expression, increased activated YAP1 expression, and increased FTH1 transcription and protein expression, protecting against ferroptosis. Conclusion GPR30 activation inhibited ferroptosis in chondrocytes by suppressing YAP1 phosphorylation, which regulates FTH1 expression. The Translational Potential of this Article : These results provide a novel potential target for therapeutic OA interventions.

Gefitinib for Epidermal Growth Factor Receptor Activated Osteoarthritis Subpopulation Treatment

Targeting cartilage EGFR pathway for osteoarthritis treatment

Reduced Egfr Signaling Enhances Cartilage Destruction in A Mouse Osteoarthritis Model

A Novel Fibroblast Growth Factor Receptor 1 Inhibitor Protects Against Cartilage Degradation in a Murine Model of Osteoarthritis

Epidermal growth factor receptor (EGFR) as a therapeutic target in rheumatoid arthritis

Therapeutic effects of gefitinib-encapsulated thermosensitive injectable hydrogel in intervertebral disc degeneration

Delivery of Epidermal Growth Factor Receptor Inhibitor Via a Customized Collagen Scaffold Promotes Meniscal Defect Regeneration in a Rabbit Model.

Molecular Mechanism Study of EGFR Allosteric Inhibitors Using Molecular Dynamics Simulations and Free Energy Calculations

The Critical Role of the Epidermal Growth Factor Receptor in Endochondral Ossification

EGFR Signaling is Critical for Maintaining the Superficial Layer of Articular Cartilage and Preventing Osteoarthritis Initiation

Reduced Epidermal Growth Factor Receptor ( EGFR ) Signaling Enhances Cartilage Destruction in Mouse Osteoarthritis Model

EGFR Signaling Is Required for Maintaining Adult Cartilage Homeostasis and Attenuating Osteoarthritis Progression

The Role of EGFR Signaling in Age-Related Osteoporosis in Mouse Cortical Bone

EGFR Signaling: Friend or Foe for Cartilage?

FGFC1 Selectively Inhibits Erlotinib-Resistant Non-Small Cell Lung Cancer via Elevation of ROS Mediated by the EGFR/PI3K/Akt/mTOR Pathway

Fibroblast growth factors: Potential novel targets for regenerative therapy of osteoarthritis

Intra-Articular Injection of (−)-Epigallocatechin 3-Gallate (EGCG) Ameliorates Cartilage Degeneration in Guinea Pigs with Spontaneous Osteoarthritis

GSK5182, 4-Hydroxytamoxifen Analog, a New Potential Therapeutic Drug for Osteoarthritis

G protein-coupled receptor 30 activation inhibits ferroptosis and protects chondrocytes against osteoarthritis

The protective effect of Ergolide in osteoarthritis: In vitro and in vivo studies

EGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy.